Muhannad Aljoulani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Muhannad Aljoulani has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Fabio Maria Valenzi
Department of Urology University of Illinois at Chicago Chicago IL USA
2 shared publications - Hakan Bahadir Haberal
Department of Urology, Ankara Etlik City Hospital, Ministry of Health, University of Health Sciences, Ankara, Turkiye
2 shared publications - Ruben Sauer Calvo
Department of Urology, University of Illinois at Chicago, Chicago, IL, USA
2 shared publications Simone Crivellaro
Department of Urology, University of Illinois at Chicago, Chicago, IL 60607, USA
2 shared publicationsAlice O’LEary
Department of Urology, University Hospital Southampton NHS Foundation Trust, UK
1 shared publicationAndrea Fuschi
Urology Unit, Department of Medico-Surgical Sciences and Biotechnologies, Faculty of Pharmacy and Medicine, Sapienza University of Rome, 04100 Latina, Italy
1 shared publication
Latest Publications
- 15 July 2026
- Published by SAGE Publications in Journal of Clinical Urology
- Vol. 19 (5) , 451-462
Micro-ultrasound in the diagnostic pathway of prostate cancer: Emerging roles in initial detection and active surveillance
Background: Multiparametric magnetic resonance imaging has reshaped prostate cancer diagnostics but is limited by cost, accessibility, and workflow complexity. High-resolution micro-ultrasound offers real-time lesion visualization and targeted biopsy capability as a potential complementary imaging modality. Methods: A narrative review of the literature was conducted using PubMed and Embase from inception to March 2026. Search terms included “micro-ultrasound,” “MicroUS,” “29 MHz ultrasound,” “PRI-MUS,” “prostate cancer,” “clinically significant prostate cancer,” “biopsy,” and “active surveillance.” Priority was given to randomized trials, prospective comparative studies, systematic reviews, and meta-analyses. Results: Micro-ultrasound demonstrates high sensitivity for clinically significant prostate cancer, with randomized evidence from the OPTIMUM trial supporting noninferiority to magnetic resonance imaging–based diagnostic pathways. Prospective studies suggest that micro-ultrasound enables real-time lesion targeting and may detect clinically significant prostate cancer not identified by multiparametric magnetic resonance imaging, supporting a complementary role in combined diagnostic strategies. However, specificity and biopsy-avoidance capacity remain lower than those of multiparametric magnetic resonance imaging. In active surveillance, micro-ultrasound serves as an adjunct for targeted biopsy but does not replace MRI-based protocols. Conclusions: Micro-ultrasound is a promising complementary imaging modality that enhances real-time targeting and workflow efficiency. Its primary role lies in integration within multimodal diagnostic pathways rather than replacement of multiparametric magnetic resonance imaging. Further multicentre validation and standardization are required to define its role in clinical practice. Level of evidence: Not applicable.
- 15 July 2026
- Published by SAGE Publications in Journal of Clinical Urology
- Vol. 19 (5) , 451-462
Micro-ultrasound in the diagnostic pathway of prostate cancer: Emerging roles in initial detection and active surveillance
Background: Multiparametric magnetic resonance imaging has reshaped prostate cancer diagnostics but is limited by cost, accessibility, and workflow complexity. High-resolution micro-ultrasound offers real-time lesion visualization and targeted biopsy capability as a potential complementary imaging modality. Methods: A narrative review of the literature was conducted using PubMed and Embase from inception to March 2026. Search terms included “micro-ultrasound,” “MicroUS,” “29 MHz ultrasound,” “PRI-MUS,” “prostate cancer,” “clinically significant prostate cancer,” “biopsy,” and “active surveillance.” Priority was given to randomized trials, prospective comparative studies, systematic reviews, and meta-analyses. Results: Micro-ultrasound demonstrates high sensitivity for clinically significant prostate cancer, with randomized evidence from the OPTIMUM trial supporting noninferiority to magnetic resonance imaging–based diagnostic pathways. Prospective studies suggest that micro-ultrasound enables real-time lesion targeting and may detect clinically significant prostate cancer not identified by multiparametric magnetic resonance imaging, supporting a complementary role in combined diagnostic strategies. However, specificity and biopsy-avoidance capacity remain lower than those of multiparametric magnetic resonance imaging. In active surveillance, micro-ultrasound serves as an adjunct for targeted biopsy but does not replace MRI-based protocols. Conclusions: Micro-ultrasound is a promising complementary imaging modality that enhances real-time targeting and workflow efficiency. Its primary role lies in integration within multimodal diagnostic pathways rather than replacement of multiparametric magnetic resonance imaging. Further multicentre validation and standardization are required to define its role in clinical practice. Level of evidence: Not applicable.
- Open Access
Single-Port Versus Multi-Port Robotic Radical Prostatectomy in Elderly Patients
Background/Objectives: Single-port radical prostatectomy (SP-RARP) has been demonstrated to be a feasible and safe procedure, even in older patients. This study aims to compare multi-port radical prostatectomy (MP-RARP) with SP-RARP, with a particular focus on elderly patients. Methods: Patients who underwent SP-RARP or MP-RARP between January 2018 and December 2023 were retrospectively analyzed. Patients undergoing concomitant surgical procedures or diagnosed with locally advanced prostate cancer were excluded from this study. Patients were then stratified into two groups: Group A (age < 65 years) and Group B (age ≥ 65 years). Results: A total of 338 patients (153 MP-RARP and 185 SP-RARP) were retrospectively collected. In Group B, the length of stay (in hours) was significantly shorter for SP procedures compared to MP (18 (20.8) vs. 35 (17); p = 0.002), with a higher rate of same-day discharge in favor of SP (45 (54.9%) vs. 9 (16.7%); p < 0.001). Additionally, MP patients in Group B had a higher incidence of postoperative complications at both 30 days (19(35.2%) vs. 13 days (15.9%); p = 0.009) and 90 days (21(38.9%) vs. 14 days (17.1%); p = 0.004) compared to those undergoing SP. Multivariable logistic regression analysis identified SP as a protective factor against postoperative complications at 30 days (Odds ratio: 0.41; 95% CI: 0.15, 0.97; p value = 0.027) and 90 days (Odds ratio: 0.38; 95% CI: 0.17,0.788; p = 0.024). Additionally, length of stay was associated with postoperative complications at 30 days (Odds ratio: 1.02; 95% CI: 1.01, 1.13; p value = 0.046). Conclusions: SP-RARP is a safe and feasible option for elderly patients, offering a lower incidence of short-term postoperative complications compared to MP-RARP. Furthermore, same-day discharge is feasible even in elderly patients undergoing SP-RARP.
Open AccessSingle-Port Versus Multi-Port Robotic Radical Prostatectomy in Elderly Patients
Background/Objectives: Single-port radical prostatectomy (SP-RARP) has been demonstrated to be a feasible and safe procedure, even in older patients. This study aims to compare multi-port radical prostatectomy (MP-RARP) with SP-RARP, with a particular focus on elderly patients. Methods: Patients who underwent SP-RARP or MP-RARP between January 2018 and December 2023 were retrospectively analyzed. Patients undergoing concomitant surgical procedures or diagnosed with locally advanced prostate cancer were excluded from this study. Patients were then stratified into two groups: Group A (age < 65 years) and Group B (age ≥ 65 years). Results: A total of 338 patients (153 MP-RARP and 185 SP-RARP) were retrospectively collected. In Group B, the length of stay (in hours) was significantly shorter for SP procedures compared to MP (18 (20.8) vs. 35 (17); p = 0.002), with a higher rate of same-day discharge in favor of SP (45 (54.9%) vs. 9 (16.7%); p < 0.001). Additionally, MP patients in Group B had a higher incidence of postoperative complications at both 30 days (19(35.2%) vs. 13 days (15.9%); p = 0.009) and 90 days (21(38.9%) vs. 14 days (17.1%); p = 0.004) compared to those undergoing SP. Multivariable logistic regression analysis identified SP as a protective factor against postoperative complications at 30 days (Odds ratio: 0.41; 95% CI: 0.15, 0.97; p value = 0.027) and 90 days (Odds ratio: 0.38; 95% CI: 0.17,0.788; p = 0.024). Additionally, length of stay was associated with postoperative complications at 30 days (Odds ratio: 1.02; 95% CI: 1.01, 1.13; p value = 0.046). Conclusions: SP-RARP is a safe and feasible option for elderly patients, offering a lower incidence of short-term postoperative complications compared to MP-RARP. Furthermore, same-day discharge is feasible even in elderly patients undergoing SP-RARP.
- 1 March 2025
- Published by SAGE Publications in Journal of Laparoendoscopic & Advanced Surgical Techniques
- Vol. 35 (3) , 240-246
Optimizing Prostate Cancer Surgery for Seniors: Single-Port Robotic-Assisted Platform
Background: The Da Vinci single-port (SP) platform is being used more frequently in radical prostatectomy (RP). In this study we aimed to compare the complications and oncological outcomes of the Da Vinci SP platform in robotic-assisted radical prostatectomy (SP-RARP) between elderly and young age-groups and to further examine differences between young-old and old-old patients. Materials and Methods: Data from 193 patients who underwent SP-RARP between December 2018 and June 2024 were analyzed. Patients were categorized into two age-groups: young (18-64 years) and elderly (65+ years). The elderly group was further divided into young-old (65-69 years) and old-old (70+ years) subgroups. The analysis considered variables related to patient characteristics, intraoperative outcomes, complications, and postoperative oncological outcomes. Results: The median age of the patients at the time of surgery was 64 (9.5) years. The intraoperative complication rate of 1.6%, with no cases requiring conversion to open surgery. The overall incidence of postoperative adverse events was 24.4%, and the 30-day readmission rate was 11.4%. Intraoperative complications and 30-day readmission rates were similar between groups (P = .593 and P = .821, respectively), while the postoperative complication rate was significantly higher in the younger patient group (P = .012). The median length of hospital stay (LOS) was 7 (22) hours and 110 (57%) patients were discharged on the same day (SDD). LOS and SDD rates were similar between groups (P = .389 and P = .529, respectively). The 3-year and 5-year biochemical recurrence (BCR)-free survival rates were 80.5% and 75.1%, respectively. The BCR-free survival rates were similar between both young and elderly patients and between the young-old and old-old groups (P = .751, P = .765, respectively). Conclusion: SP-RARP is a feasible option for elderly patients, delivering acceptable oncological outcomes with a low incidence of postoperative complications.
- 1 March 2025
- Published by SAGE Publications in Journal of Laparoendoscopic & Advanced Surgical Techniques
- Vol. 35 (3) , 240-246
Optimizing Prostate Cancer Surgery for Seniors: Single-Port Robotic-Assisted Platform
Background: The Da Vinci single-port (SP) platform is being used more frequently in radical prostatectomy (RP). In this study we aimed to compare the complications and oncological outcomes of the Da Vinci SP platform in robotic-assisted radical prostatectomy (SP-RARP) between elderly and young age-groups and to further examine differences between young-old and old-old patients. Materials and Methods: Data from 193 patients who underwent SP-RARP between December 2018 and June 2024 were analyzed. Patients were categorized into two age-groups: young (18-64 years) and elderly (65+ years). The elderly group was further divided into young-old (65-69 years) and old-old (70+ years) subgroups. The analysis considered variables related to patient characteristics, intraoperative outcomes, complications, and postoperative oncological outcomes. Results: The median age of the patients at the time of surgery was 64 (9.5) years. The intraoperative complication rate of 1.6%, with no cases requiring conversion to open surgery. The overall incidence of postoperative adverse events was 24.4%, and the 30-day readmission rate was 11.4%. Intraoperative complications and 30-day readmission rates were similar between groups (P = .593 and P = .821, respectively), while the postoperative complication rate was significantly higher in the younger patient group (P = .012). The median length of hospital stay (LOS) was 7 (22) hours and 110 (57%) patients were discharged on the same day (SDD). LOS and SDD rates were similar between groups (P = .389 and P = .529, respectively). The 3-year and 5-year biochemical recurrence (BCR)-free survival rates were 80.5% and 75.1%, respectively. The BCR-free survival rates were similar between both young and elderly patients and between the young-old and old-old groups (P = .751, P = .765, respectively). Conclusion: SP-RARP is a feasible option for elderly patients, delivering acceptable oncological outcomes with a low incidence of postoperative complications.